We would like to welcome two new members to the team of FHI Clinical Scientific Advisory Experts, who serve as consultants to support our global programs and operations.
Missed the webinar? Watch it now!
Missed the webinar? Watch it now!
We envision a world where advances in vaccines and medicines help all people live longer, healthier lives.
We offer a unique combination of in-country technical, regulatory and cultural knowledge and an established global presence in Africa, Asia, Europe, Latin America and North America.
We adapt our processes and workflow as your study needs change. No matter how large or small the project, we remain agile and exact, because your research demands it.
We have research at our core. A subsidiary of FHI 360, we benefit from our parent company’s 40+ year history of clinical research and success in creating and growing CROs.
Our mission is to address unmet research needs and achieve maximum social impact by supporting the development of life-saving vaccines and medicines.
Let us help you enter hard-to-reach markets and access the right patient populations.
Tailored services to meet your needs, from protocol design and site assessments to trial planning, implementation and management.
Ability to address challenges across dozens of therapeutic areas, including infectious diseases (IDs), neglected tropical diseases (NTDs), emerging and reemerging diseases, and pediatric studies.
Leverage established partnerships with leading public and private medical research organizations, pharmaceutical and biotechnology companies, academic institutions, the U.S. National Institutes of Health (NIH), the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Agency for International Development (USAID).
As we monitor the rapidly changing COVID-19 situation, reliable data sources are crucial. We recommend this resource from Johns Hopkins University to better understand the pandemic’s impact.
The data sources include the World Health Organization, the U.S. Centers for Disease Control and Prevention, the European Center for Disease Prevention and Control, the National Health Commission of the People’s Republic of China, 1point3acres, Worldometers.info, BNO, state and national government health departments, local media reports, and the DXY, one of the world’s largest online communities for physicians, health care professionals, pharmacies and facilities.
December 4, 2020
Phase I/II studies to evaluate human placental hematopoietic stem cell–derived natural killer (NK) cell therapy to treat COVID-19 in hospitalized adults are currently ongoing as part of our partnership with the Infectious Disease Research Institute (IDRI).
November 15-19, 2020
Attending the ASTMH 2020 Annual Meeting? Schedule a meeting with an FHI Clinical team member who will be in attendance at the event or stop by our booth
“Educate, Empower, Elevate!” was the theme for the most recent conference for Women of Color in Pharma (WOCIP), a nonprofit aiming to promote the development and advancement of women of color who are employed in the pharmaceutical industry. We asked FHI Clinical team members, Tafoya Hubbard and LaTonya Jones to share some thoughts about their experiences during the 2020 two-day virtual event.
FHI Clinical Headquarters
359 Blackwell Street, Suite 200
Durham, NC 27701 USA